Kiklin capsules
Pre-clinicalCompletedDevelopment Stage
Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis
Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis
Jan 1, 2013 → Dec 1, 2016
About Kiklin capsules
Kiklin capsules is a pre-clinical stage product being developed by Astellas Pharma for Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT01901107. Target conditions include Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis.
What happened to similar drugs?
20 of 20 similar drugs in Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01901107 | Pre-clinical | Completed |
Competing Products
20 competing products in Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levofloxacin 500 | Dr. Reddy's Laboratories | Pre-clinical | 23 |
| mRNA-0184 | Moderna | Phase 1 | 0 |
| Lubiprostone + Lubiprostone + Placebo | Dr. Reddy's Laboratories | Phase 3 | 37 |
| macitentan 10 mg | BML, Inc. | Phase 3 | 32 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 29 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 36 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 23 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 35 |
| THB001 | Third Harmonic Bio | Phase 1 | 11 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 26 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 14 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 29 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 40 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 29 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 44 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 35 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 42 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 21 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 27 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 25 |